Diarylsulfonylureas--a new class of antitumor agents.
Diarylsulfonylureas (DSU) represent a new class of antitumor agents. DSU exhibit an exceptionally broad spectrum of activity against solid tumors. They show different toxicity to conventional anticancer agents and exhibit no cross-resistance with existing anticancer agents. In particular they have an unknown, but unique, potentially novel mechanism of action. Sulofenur is the first DSU to progress to clinical evaluation. The dose-limiting toxicity in humans is anemia and methemoglobinemia. Recently, DSU with novel structural features have also been reported to exhibit potent antitumor activity, demonstrating structural diversity of DSU antitumor agents.